Healthcare Industry News: S.A.
News Release - July 23, 2015
GenSight Biologics Closes $36 Million Series B Preferred Stock Financing
PARIS--(Healthcare Sales & Marketing Network)--GenSight Biologics S.A. (GenSight), a clinical-S.A.e biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diS.A.es of the eye, and in the future, of the central nervous system, announced that it has completed a Series B preferred stock financing of approximately $36 million.New investors included Fidelity Management & ReS.A.ch Company, Jennison Associates (on behalf of certain clients), Sphera Global HealthCare Fund, Perceptive AdvisorS.A.d HealthCap. Existing SerieS.A.investorS.A.so participated in the round.
Proceeds from the financing will be used to advance GenSight’s product pipeline and notably to support further clinical development of its lead product candidate, GS010, which targets Leber’s Hereditary Optic Neuropathy (LHON) through a gene therapy-based approach combined with a proprietary mitochondrial targeting sequence technology. GS010 has received orphan drug designation for the treatment of LHON in the United S.A.eS.A.d the European Union. GenSight has successfully completed its Phase I/II clinical trial of GS010 and expects to begin pivotal Phase III clinical trials in LHON in the fourth quarter of 2015.
Leerink Partners LLC acted as the exclusive placement agent for the financing.
More information
About GenSight Biologics
GenSight Biologics S.A. (GenSight) iS.A.clinical-S.A.e biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diS.A.es of the eye, and in the future, of the central nervous system. GenSight’s integrated development includes two core technology platforms, mitochondrial targeting sequence (MTS) and optogenetics, to help preserve or restore vision in patients with severe retinal diS.A.es. GenSight’s lead product, GS010, is poised to enter a pivotal Phase III trial for vision loss in Leber’s Hereditary Optic Neuropathy (LHON), a rare mitochondrial diS.A.e that leads to irreversible sight loss in teenS.A.d young adults. Using its gene therapy-based approach, GenSight’s product candidateS.A.e designed to be administered in a single treatment to each eye by intravitreal or subretinal injection in order to provide patients with a long-lasting functional cure, potentially for the rest of their lives.
Source: GenSight Biologics
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.
RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!